Filtered By:
Source: Journal of Stroke and Cerebrovascular Diseases
Drug: Activase

This page shows you your search results in order of date. This is page number 3.

Order by Relevance | Date

Total 72 results found since Jan 2013.

Safety and Efficacy of Intravenous Low-Dose Alteplase in Relative Contraindication Patients with Acute Ischemic Stroke
The purpose of this study was to investigate the safety and efficacy of intravenous low-dose alteplase for acute ischemic stroke patients with relative contraindications.
Source: Journal of Stroke and Cerebrovascular Diseases - March 16, 2018 Category: Neurology Authors: Tsuyoshi Ohta, Kenji Okada, Maki Fukuda, Noritaka Masahira, Toshiki Matsuoka, Takaya Tsuno, Mitsuhiro Takemura Source Type: research

Cerebral Microbleeds are an Independent Predictor of Hemorrhagic Transformation Following Intravenous Alteplase Administration in Acute Ischemic Stroke
The objective of our study was to evaluate clinical, laboratory, and imaging predictors on forecasting the risk of hemorrhagic transformation following treatment with rt-PA. We also evaluated the factors associated with cerebral microbleeds that increase the risk of hemorrhagic transformation.
Source: Journal of Stroke and Cerebrovascular Diseases - February 2, 2018 Category: Neurology Authors: Nandakumar Nagaraja, Nudrat Tasneem, Amir Shaban, Sudeepta Dandapat, Uzair Ahmed, Bruno Policeni, Heena Olalde, Hyungsub Shim, Edgar A. Samaniego, Connie Pieper, Santiago Ortega-Gutierrez, Enrique C. Leira, Harold P. Adams Source Type: research

Outcome of Acute Ischemic Stroke after the Treatment with Edaravone and 0.6 Mg/Kg Alteplase in Japanese Patients with Diabetes
We investigated how diabetes mellitus (DM) affects the outcome of acute ischemic stroke (AIS), comparing with the outcomes in those who had hypertension (HT) and atrial fibrillation (AF).
Source: Journal of Stroke and Cerebrovascular Diseases - January 18, 2018 Category: Neurology Authors: Norio Tanahashi, Takenori Yamaguchi, Hideto Awano, Hiroaki Matsuda Source Type: research

Clinical Study of Intravenous, Low-Dose Recombinant Tissue Plasminogen Activator for Acute Cerebral Infarction: Comparison of Treatment within 3  Hours versus 3-4.5 Hours
An intravenous recombinant tissue plasminogen activator (rt-PA, alteplase .6  mg/kg) for acute cerebral infarction within 3 hours of onset was approved in Japan in 2005. The treatment window was subsequently extended to within 4.5 hours of onset. However, few Japanese studies have compared the efficacy and safety of rt-PA therapy between patients treated within 3 hou rs and patients treated within 3-4.5 hours.
Source: Journal of Stroke and Cerebrovascular Diseases - December 5, 2017 Category: Neurology Authors: Ichiro Deguchi, Norio Tanahashi, Masaki Takao Source Type: research

Incidental Thrombotic Thrombocytopenic Purpura during Acute Ischemic Stroke and Thrombolytic Treatment
In this study, a patient with AIS and thrombotic thrombocytopenic purpura (TTP) symptoms during thrombolytic treatment was presented.
Source: Journal of Stroke and Cerebrovascular Diseases - November 28, 2017 Category: Neurology Authors: İbrahim Acır, Hacı Ali Erdoğan, Vildan Yayla, Nilay Taşdemir, Murat Çabalar Tags: Case Report Source Type: research

Thrombolytic Therapy of Acute Ischemic Stroke during Early Pregnancy
Thrombolytic treatment (recombinant tissue plasminogen activator [rt-PA]) has established efficacy in acute ischemic stroke, but pregnancy has been an exclusion criterion for all clinical trials that validated alteplase in acute stroke, so our knowledge about its use in this condition is limited.Herein we report the successful use of intravenous rt-PA thrombolysis, uncomplicated by neither hemorrhage development nor other complication in a woman who was 13 weeks pregnant with acute ischemic stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - November 28, 2017 Category: Neurology Authors: Anne Landais, Hugo Chaumont, Rachel Dellis Tags: Case Studies Source Type: research

Incidental Thrombotic Thrombocytopenic Purpura during Acute Ischemic Stroke and Thrombolytic Treatment
In this study, a patient with AIS and thrombotic thrombocytopenic purpura (TTP) symptoms during thrombolytic treatment was presented.
Source: Journal of Stroke and Cerebrovascular Diseases - November 28, 2017 Category: Neurology Authors: İbrahim Acır, Hacı Ali Erdoğan, Vildan Yayla, Nilay Taşdemir, Murat Çabalar Tags: Case Report Source Type: research

Safety of Intravenous Thrombolysis in Chronic Intracranial Hemorrhage: A Five-Year Multicenter Study
Although the recently updated U.S. alteplase label removed “history of intracranial hemorrhage (ICH)” as a contraindication, there are very limited data on the safety of intravenous thrombolysis (IVT) in acute ischemic stroke (AIS) patients with chronic ICH. We sought to evaluate IVT safety in AIS patients with a history of ICH.
Source: Journal of Stroke and Cerebrovascular Diseases - October 31, 2017 Category: Neurology Authors: Ramin Zand, Georgios Tsivgoulis, Alireza Sadighi, Mantinderpreet Singh, Michael McCormack, Shima Shahjouei, Nitin Goyal, Nariman Noorbakhsh-Sabet, Anne W. Alexandrov, Andrei V. Alexandrov Source Type: research

Icatibant as a Potential Treatment of Life-Threatening Alteplase-Induced Angioedema
Severe orolingual angioedema is a life-threatening complication of alteplase treatment for acute ischemic stroke that occurs during alteplase infusion or in the first 2 hours afterward. Currently, there are no proven therapies, although glucocorticoids, antihistamines, and adrenaline are sometimes used. Intubation is required if significant airway compromise supervenes. The incidence is .2%-5.1%, and risk factors include treatment with angiotensin-converting enzyme inhibitors and total insular infarcts.
Source: Journal of Stroke and Cerebrovascular Diseases - October 30, 2017 Category: Neurology Authors: Edmund Cheong, Lizzie Dodd, William Smith, Timothy Kleinig Tags: Case Studies Source Type: research

Intra-Arterial Alteplase Thrombolysis during Mechanical Thrombectomy for Acute Ischemic Stroke
Intra-arterial alteplase (IA tPA) is commonly used during mechanical thrombectomy for acute ischemic stroke in patients with large-vessel occlusion, but specific indications and applications for its use remain undefined.
Source: Journal of Stroke and Cerebrovascular Diseases - August 23, 2017 Category: Neurology Authors: Daniel M. Heiferman, Daphne D. Li, Nathan C. Pecoraro, Angela M. Smolenski, Asterios Tsimpas, William W. Ashley Source Type: research

Myocardial Infarction Following Intravenous Thrombolysis for Acute Ischemic Stroke: Case Report and Literature Review
We describe a case of early anterior myocardial infarction during intravenous thrombolysis for stroke and review the current literature.
Source: Journal of Stroke and Cerebrovascular Diseases - April 20, 2017 Category: Neurology Authors: Marina Mannino, Salvatore Asciutto, Valeria Terruso, Matilde Gammino, Melchiorre Gilberto Cellura, Serena Monaco Tags: Case Studies Source Type: research

Thrombolysis with tPA 3-4.5  h after acute ischemic stroke in 5 hospital groups in Japan
Clinical data from Japan on the safety and realworld outcomes of alteplase (tPA) thrombolysis in the extended therapeutic window are lacking. The aim of this study was to assess the safety and real-world outcomes of tPA administered within 3-4.5  h of stroke onset. The study comprised consecutive acute ischemic stroke patients (n = 177) admitted across five hospitals between September 2012 and August 2014. Patients received intravenous tPA within
Source: Journal of Stroke and Cerebrovascular Diseases - March 18, 2017 Category: Neurology Authors: Ryuta Morihara, Syoichiro Kono, Toru Yamashita, Kentaro Deguchi, Yasuhiro Manabe, Takako Yoshiki, Kenichi Kashihara, Satoshi Inoue, Hideki Kiriyama, Koji Abe Source Type: research